tradingkey.logo

Exact Sciences Corp

EXAS
67.030USD
-0.720-1.06%
終値 11/14, 16:00ET15分遅れの株価
12.70B時価総額
損失額直近12ヶ月PER

Exact Sciences Corp

67.030
-0.720-1.06%

詳細情報 Exact Sciences Corp 企業名

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Exact Sciences Corpの企業情報

企業コードEXAS
会社名Exact Sciences Corp
上場日Jan 30, 2001
最高経営責任者「CEO」Mr. Kevin T. Conroy
従業員数6900
証券種類Ordinary Share
決算期末Jan 30
本社所在地5505 Endeavor Lane
都市MADISON
証券取引所NASDAQ Capital Market Consolidated
United States of America
郵便番号53719
電話番号16082845700
ウェブサイトhttps://www.exactsciences.com/
企業コードEXAS
上場日Jan 30, 2001
最高経営責任者「CEO」Mr. Kevin T. Conroy

Exact Sciences Corpの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.14M
-20.54%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
60.76K
-16.49%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+18.67%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
28.90K
+22.97%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.04K
-11.04%
Ms. Leslie L. Trigg
Ms. Leslie L. Trigg
Independent Director
Independent Director
17.17K
+80.75%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
16.38K
+156.47%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
13.84K
--
Mr. Michael J. (Mike) Barber, M.D.
Mr. Michael J. (Mike) Barber, M.D.
Independent Director
Independent Director
13.14K
+121.18%
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.14M
-20.54%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
60.76K
-16.49%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+18.67%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
28.90K
+22.97%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.04K
-11.04%
Ms. Leslie L. Trigg
Ms. Leslie L. Trigg
Independent Director
Independent Director
17.17K
+80.75%

収益内訳

通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Commercial
387.50M
47.78%
Medicare Parts B & C
274.49M
33.84%
Other
93.84M
11.57%
International
55.26M
6.81%
地域別USD
会社名
収益
比率
United States (Country)
755.83M
93.19%
Outside of united states
55.26M
6.81%
事業別
地域別
事業別USD
会社名
収益
比率
Commercial
387.50M
47.78%
Medicare Parts B & C
274.49M
33.84%
Other
93.84M
11.57%
International
55.26M
6.81%

株主

更新時刻: 23 hours ago
更新時刻: 23 hours ago
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.38%
Capital World Investors
8.52%
Fidelity Management & Research Company LLC
8.12%
BlackRock Institutional Trust Company, N.A.
3.78%
Wellington Management Company, LLP
2.81%
他の
67.40%
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.38%
Capital World Investors
8.52%
Fidelity Management & Research Company LLC
8.12%
BlackRock Institutional Trust Company, N.A.
3.78%
Wellington Management Company, LLP
2.81%
他の
67.40%
種類
株主統計
比率
Investment Advisor
52.84%
Investment Advisor/Hedge Fund
26.25%
Hedge Fund
6.43%
Pension Fund
2.25%
Research Firm
2.03%
Individual Investor
0.91%
Bank and Trust
0.56%
Sovereign Wealth Fund
0.48%
Private Equity
0.32%
他の
7.92%

機関投資家保有株

更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
1362
183.28M
96.81%
-19.18M
2025Q2
1403
202.48M
106.98%
+2.53M
2025Q1
1424
199.78M
106.03%
-445.52K
2024Q4
1411
200.72M
108.09%
-225.66K
2024Q3
1375
190.82M
103.28%
-5.17M
2024Q2
1358
185.25M
100.40%
+6.59M
2024Q1
1347
168.41M
92.78%
-6.10M
2023Q4
1356
165.31M
91.41%
-11.01M
2023Q3
1337
167.70M
92.83%
-6.22M
2023Q2
1354
166.38M
92.24%
-10.65M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
17.87M
9.44%
+303.00K
+1.73%
Jun 30, 2025
Capital World Investors
18.20M
9.61%
+364.75K
+2.05%
Jun 30, 2025
Fidelity Management & Research Company LLC
23.28M
12.3%
-852.45K
-3.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
7.04M
3.72%
-640.89K
-8.35%
Jun 30, 2025
Wellington Management Company, LLP
12.00M
6.34%
-497.53K
-3.98%
Jun 30, 2025
State Street Investment Management (US)
5.38M
2.84%
-1.23M
-18.67%
Jun 30, 2025
MFS Investment Management
2.96M
1.57%
+1.46M
+97.24%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.24M
1.71%
-29.40K
-0.90%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
First Trust Nasdaq Lux Digi Health Solutions ETF
3.78%
First Trust NYSE Arca Biotechnology Index Fund
3.27%
Invesco Biotechnology & Genome ETF
3.17%
Alger Mid Cap 40 ETF
2.49%
First Trust Indxx Medical Devices ETF
2.34%
SPDR S&P Biotech ETF
2.06%
iShares Health Innovation Active ETF
1.84%
Franklin Genomic Advancements ETF
1.81%
ROBO Global Healthcare Technology & Innovation ETF
1.74%
VanEck Biotech ETF
1.44%
詳細を見る
First Trust Nasdaq Lux Digi Health Solutions ETF
比率3.78%
First Trust NYSE Arca Biotechnology Index Fund
比率3.27%
Invesco Biotechnology & Genome ETF
比率3.17%
Alger Mid Cap 40 ETF
比率2.49%
First Trust Indxx Medical Devices ETF
比率2.34%
SPDR S&P Biotech ETF
比率2.06%
iShares Health Innovation Active ETF
比率1.84%
Franklin Genomic Advancements ETF
比率1.81%
ROBO Global Healthcare Technology & Innovation ETF
比率1.74%
VanEck Biotech ETF
比率1.44%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし
KeyAI